Tag: #MinimalChangeDisease
-
Rituximab in Adult Minimal Change DiseaseMechanisms and Clinical Research Progress
Introduction:Minimal Change Disease (MCD) is a significant cause of nephrotic syndrome in adults, often leading to severe proteinuria, edema, and hypoalbuminemia. While corticosteroids remain the first-line treatment, Rituximab (RTX), a monoclonal antibody targeting CD20, has emerged as a promising therapy for refractory cases. This article explores the mechanisms of RTX and its clinical applications in…
-
Rituximab in Adult Minimal Change Disease: A Breakthrough in Nephrotic Syndrome Treatment
Introduction Minimal Change Disease (MCD) is a prevalent form of nephrotic syndrome, particularly in children, but also affects adults. The exact pathogenesis of MCD remains unclear, but emerging research highlights the roles of both T cells and B cells in its development. Rituximab (RTX), a monoclonal antibody targeting CD20, has gained attention as a promising…
Heighten Science Publications Inc. 